IGF-1 LR3

Mechanism of action

IGF-1 LR3 is a recombinant analogue of human insulin-like growth factor 1 (IGF-1) engineered specifically for cell-culture and research applications where extended half-life and reduced IGFBP interference are desirable. The native human IGF-1 protein comprises 70 amino acids arranged in a compact tertiary structure with three intrachain disulfide bonds; native IGF-1 has a plasma half-life of only 10-20 minutes because approximately 98% of circulating IGF-1 is bound to IGF-binding proteins (predominantly IGFBP-3 with the acid-labile subunit ALS), which sequesters IGF-1 from receptor engagement and constrains bioavailable free IGF-1 to a small fraction of total. IGF-1 LR3 incorporates two engineering modifications that together substantially reduce IGFBP binding. First, the N-terminal 13-amino-acid extension (giving the 'Long' designation) adds a sequence that interferes with the IGF-1 binding pocket on IGFBP-3, reducing the peptide's residence time in the IGFBP-bound compartment. Second, the glutamate-to-arginine substitution at position 3 (the 'R3' or 'Arg3' designation, contributing the '3' to the name) further disrupts IGFBP binding through the specific arginine side chain's effect on the binding interface. The combined effect is IGFBP-3 binding affinity reduced by approximately 50- to 100-fold versus native IGF-1, with corresponding elevation of free bioactive peptide concentration and substantial extension of functional plasma half-life to 20-30 hours. Critically, the IGF-1 receptor (IGF-1R) binding affinity is preserved by the LR3 modifications — the receptor engagement mechanism is unchanged from native IGF-1. IGF-1 LR3 binds IGF-1R with affinity comparable to native IGF-1, triggering the IRS-1/PI3K/Akt and Ras/MAPK signalling cascades that mediate IGF-1's anabolic effects on protein synthesis, cell proliferation, cell survival, and metabolic function. Downstream effects include tissue growth, protein synthesis in skeletal muscle and other tissues, chondrocyte and osteoblast proliferation in cartilage and bone, and metabolic effects on glucose disposal. The extended half-life and increased free-peptide bioavailability produce materially larger IGF-1 signalling effects at equivalent peptide doses relative to native IGF-1. This is the primary practical utility of the LR3 modifications for research applications — a smaller and more manageable amount of peptide can produce sustained IGF-1 signalling effects that would require substantially larger and more frequent native IGF-1 dosing. In tissue-repair research contexts, IGF-1 LR3 is studied for tendon and skeletal-muscle repair applications where sustained IGF-1 signalling supports proliferation of tenocytes, myoblasts, and satellite cells. In cartilage and joint research, IGF-1 LR3 supports chondrocyte proliferation and extracellular matrix synthesis. In diabetes research, IGF-1 LR3's insulin-mimetic effects at IGF-1R (which shares ~60% sequence homology with the insulin receptor) contribute to research on IGF-1 pharmacology in insulin resistance contexts.

IGF-1 LR3 combines two engineering modifications — N-terminal 13-amino-acid extension and Arg3 substitution — that together reduce IGFBP-3 binding affinity by ~50- to 100-fold versus native IGF-1, extending plasma half-life from ~10-20 minutes to ~20-30 hours while preserving IGF-1 receptor engagement. The result is a research reagent that produces materially larger IGF-1 signalling effects at equivalent peptide doses versus native IGF-1 — the practical utility that supports its widespread cell-culture research use.

— Notable finding

Research history

IGF-1 LR3 was developed by GroPep (an Australian biotechnology company subsequently acquired by others) in the early 1990s as a research and biopharmaceutical-industry cell-culture supplement. The seminal characterisation paper — Francis et al., J Endocrinol 1992 — established the enhanced mitogenic potency of the LR3 modification versus native IGF-1 in cultured-cell systems and provided the basis for the commercial product's positioning in the cell-culture-reagent market. The primary intended application was replacement of fetal bovine serum in mammalian cell culture — cell lines grown for biopharmaceutical production require growth factors including IGF-1, and IGF-1 LR3's extended half-life and reduced IGFBP interference made it a practical substitute for serum-derived IGF-1 in defined culture media. This application remains the compound's principal legitimate commercial use. Research applications have expanded across the 2000s and 2010s to include tissue-repair research (tendon, skeletal muscle, cartilage), regenerative medicine research, and various metabolic and growth-related research contexts. The compound's pharmacological utility in these contexts derives from the same reduced-IGFBP-interference mechanism that makes it useful in cell culture. Academic groups worldwide have continued to use IGF-1 LR3 as a standard research tool for IGF-1 pharmacology studies, and it appears frequently in peer-reviewed protocols for satellite-cell activation, myoblast differentiation, chondrocyte proliferation, and endocrine pharmacology. A notable secondary application space has developed in the athletic and physique-enhancement grey market. IGF-1 LR3 has substantial research-chemical-market visibility in this context, with grey-market use for muscle-hypertrophy and recovery effects despite the absence of clinical safety data supporting such use. WADA has classified IGF-1 LR3 under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as an IGF-1 analogue, and the compound is subject to anti-doping testing in relevant athletic populations. Anti-doping laboratories have developed specific analytical methods to distinguish IGF-1 LR3 from native IGF-1 in athlete-testing samples, exploiting the mass-spectrometry signature difference conferred by the N-terminal extension and the Glu-to-Arg substitution. Medicinal IGF-1 development has proceeded along a separate track. Mecasermin (recombinant human IGF-1) is licensed by FDA and EMA for severe primary IGF-1 deficiency in paediatric populations under trade names including Increlex — this is the licensed IGF-1 medicine, sequence-identical to native human IGF-1, and pharmacokinetically distinct from IGF-1 LR3. No LR3-modified IGF-1 product has entered clinical development as a medicine. IGF-1 LR3 holds no marketing authorisation as a medicine in any jurisdiction. The compound exists primarily as a cell-culture reagent commercially, with research-chemical-community and grey-market use as secondary applications.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

IGF-1 LR3's clinical safety profile in humans is limited to grey-market and case-report experience — no formal clinical trial programme has characterised the compound in humans. Pre-clinical safety data across rodent models has been favourable at research-dose ranges, with typical adverse events limited to injection-site reactions and modest metabolic effects (transient hypoglycaemia at higher doses reflecting the insulin-mimetic activity at IGF-1R). The theoretical safety concerns of sustained IGF-1 receptor activation are substantial and include: oncogenic risk through IGF-1R activation on susceptible tissues (epidemiological associations between elevated IGF-1 and multiple cancer types are well-documented); insulin resistance and disturbed glucose homeostasis with chronic dosing (paralleling but exceeding the effects of GH-axis peptides); hypoglycaemia from the insulin-mimetic activity; joint and soft-tissue overgrowth phenomena (paralleling acromegaly in extreme cases); and cardiovascular effects from chronic anabolic pharmacology. The grey-market and case-report experience has surfaced reports of substantial adverse events consistent with these theoretical concerns, including cases of hypoglycaemia, cardiomyopathy, and other complications in individuals using IGF-1 LR3 without medical supervision. The absence of formal clinical characterisation combined with the demonstrated pharmacological potency makes chronic human use particularly high-risk from a safety standpoint. In research contexts with appropriate protocols and animal-model use, the safety profile is manageable. In grey-market human use contexts, the safety profile is substantially concerning.

UK regulatory status

IGF-1 LR3 is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation as a medicine in any jurisdiction. It is not a controlled substance under the Misuse of Drugs Act 1971. IGF-1 LR3 is classified by the World Anti-Doping Agency (WADA) under S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as an IGF-1 analogue. Athletes subject to anti-doping testing should treat IGF-1 LR3 as prohibited both in-competition and out-of-competition regardless of claimed research purpose. Research-grade material is available from research-chemical and cell-culture-reagent suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. Cell-culture use in biopharmaceutical industry contexts is legitimate research application. Supply or administration of IGF-1 LR3 to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence. For animal research under ASPA, IGF-1 LR3 work in vertebrates requires standard project and personal licences. MHRA enforcement actions against IGF-1 LR3 supply for human use specifically have been documented, particularly in the athletic and physique-enhancement grey-market context.

Frequently asked questions